|1.||Kusaga, Akira: 2 articles (09/2002 - 05/2002)|
|2.||Matsuishi, T: 2 articles (02/2001 - 06/2000)|
|3.||Yamada, S: 2 articles (02/2001 - 06/2000)|
|4.||Miura, Y: 2 articles (02/2001 - 01/2000)|
|5.||Lelièvre, Bénédicte: 1 article (09/2015)|
|6.||Turcant, Alain: 1 article (09/2015)|
|7.||Le Roux, Gaël: 1 article (09/2015)|
|8.||Bretaudeau Deguigne, Marie: 1 article (09/2015)|
|9.||Boels, David: 1 article (09/2015)|
|10.||Bruneau, Chloé: 1 article (09/2015)|
|1.||Renal Insufficiency (Renal Failure)
08/05/1999 - "Effects of renal insufficiency and of aging on the pharmacokinetics of NS-49, a newly developed phenethylamine class alpha(1A)-adrenoceptor agonist eliminated mainly by renal excretion, were investigated in rats after a single administration of (14)C-NS-49. "
08/05/1999 - "Effects of renal insufficiency and aging on the pharmacokinetics of a phenethylamine class alpha(1A)-adrenoceptor agonist NS-49."
01/01/1990 - "Phenylpropanolamine (PPA) is a phenethylamine that induces a variety of effects including anorexia and weight loss. "
10/01/1986 - "The discovery that trace amine beta-phenylethylamine (PEA) has a number of properties in common with amphetamine (AMPH) has led to the suggestion that PEA may be a neuromodulator of catecholamine release or an "endogenous amphetamine." The present study compared PEA-induced behavioural changes (anorexia and hyperactivity) with AMPH-induced changes in feeding and motor activity. "
01/01/2012 - "Amphetamines or amphetamine-type stimulants (ATSs) refer to a group of pharmacological and -toxicological agents that have a common phenethylamine structural backbone and typically impart effects that include, but are not limited to, vasoconstriction, anorexia, central nervous system stimulation, and/or hallucinations. "
09/01/2015 - "This study aimed to describe typical aspects of phenethylamine poisoning in order to better inform patient care. "
09/01/2015 - "Phenethylamine poisonings may be severe in young and healthy individuals. "
09/01/2015 - "Phenethylamine poisoning cases reported to the Poison Control Center of Angers, France, from January, 2007 to December, 2013 were examined. "
09/01/2015 - "Recreational phenethylamine poisonings reported to a French poison control center."
09/01/2015 - "Substances most commonly associated with phenethylamine poisoning were cannabis (27%), ethanol (20%) and cocaine (9%). "
|4.||Parkinson Disease (Parkinson's Disease)
10/01/2013 - "Contribution of β-phenethylamine, a component of chocolate and wine, to dopaminergic neurodegeneration: implications for the pathogenesis of Parkinson's disease."
01/01/2000 - "Plasma beta-phenylethylamine (PEA) levels were determined in 27 patients with Parkinson's disease (PD) in order to evaluate its relation with the severity or clinical course of PD. "
01/01/2000 - "Plasma beta-phenylethylamine in Parkinson's disease."
12/01/1997 - "To determine the concentrations of beta-phenylethylamine (PEA) in CSF in patients with Parkinson's disease, and to evaluate the relation between concentration of PEA in CSF and severity of Parkinson's disease. "
12/01/1997 - "Decreased beta-phenylethylamine in CSF in Parkinson's disease."
|5.||Schizophrenia (Dementia Praecox)
11/01/2005 - "2-Phenylethylamine (PEA)-induced stereotypy in rodents is suggested to model psychotic symptoms of schizophrenia. "
09/01/2004 - "Changes in biological fluids levels of 2-phenylethylamine and/or in its metabolite have been reported in affective disorders, such as depression and schizophrenia. "
01/01/1978 - "Disruption of conditioned avoidance behavior by n,n-dimethyltryptamine (DMT) and stereotype by beta-phenylethylamine (PEA): animal models of attentional defects in schizophrenia."
04/01/1982 - "Platelet monoamine oxidase in schizophrenia with beta-phenylethylamine and benzylamine as substrates."
08/01/2008 - "beta-Phenylethylamine (beta-PEA), an endogenous amine synthesized in the brain, serves as a neuromodulator and is involved in the pathophysiology of various neurological disorders such as depression, schizophrenia, and attention-deficit hyperactivity disorder. "
|1.||3'- (2- amino- 1- hydroxyethyl)- 4'- fluoromethanesulfonanilide
|3.||Neurotransmitter Agents (Neurotransmitter)
|4.||Monoamine Oxidase (MAO)
|7.||Serotonin (5 Hydroxytryptamine)